health

Coronavirus: China approves a clinical trial of a candidate German vaccine

BNT162b2 vaccine, an mRNA based vaccine candidate against COVID-19, in Mainz, Germany.  The filter, which is being developed by BioNTech with Pfizer and the Chinese company Fosun Pharma, has obtained approval from the China Medical Products Administration to start an in-country trial for the candidate, according to a statement released on November 13, 2020. Photo: EPA-EFEBNT162b2 vaccine, an mRNA-based vaccine candidate against COVID-19, in Mainz, Germany.  The filter, which is being developed by BioNTech with Pfizer and the Chinese company Fosun Pharma, has obtained approval from the China Medical Products Administration to start an in-country trial for the candidate, according to a statement released on November 13, 2020. Photo: EPA-EFE

BNT162b2 vaccine, an mRNA-based vaccine candidate against COVID-19, in Mainz, Germany. The filter, which is being developed by BioNTech with Pfizer and the Chinese company Fosun Pharma, has obtained approval from the China Medical Products Administration to start an in-country trial for the candidate, according to a statement released on November 13, 2020. Photo: EPA-EFE

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button